MedTrace Logo

Cytochrome P450 2D6 (CYP 450 2D6) Genotype and Flecainide Efficacy

NCT00945867 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2011-04-05

No results posted yet for this study

Summary

The determination of the 2D6 genotype will enable us to determine the way flecainide is metabolized by the liver. Some individuals are poor metabolizers and some individuals are extensive metabolizers of the drug. This will also determine which patients will benefit from the drug.

Conditions

Sponsors & Collaborators

  • Assaf-Harofeh Medical Center

    lead OTHER_GOV

Principal Investigators

  • Moshe Sharist, MD · Assaf-Harofeh Medical Center

  • Shmuel Bar-Haim, MD · Assaf-Harofeh Medical Center

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-03-31
Completion
2010-08-31

Countries

  • Israel

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00945867 on ClinicalTrials.gov